BridgeMD
Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load
EU CTIS ID: 2022-503110-23-00
What this study is testing
To evaluate the efficacy of Rilpivirine (RPV) as part of the antiretroviral treatment regimen in HIV-infected people, to slow the progression and/or reduce liver fibrosis of any degree, measured by non-invasive tests
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Patients over 18 years of age with HIV infection who have never received antiretroviral treatment with Rilpivirine. 2. Have a stable ART regimen for at least the last 6 months. Simplifications to combination therapies will not be taken into account as long as the patient has a control of the HIV viral load after the change that confirms its undetectability. 3. Not have resistance mutations that compromise the efficacy of Rilpivirine, Dolutegravir, Tenofovir (TDF and/or TAF) or Emtricitabine. 4. Have an HIV viral load < 50 copies/ml for at least the last 6 months, 1 blip less than 500 copies/ml is allowed during this period. 5. Having an EHMG diagnosed by ultrasound or a CAP measurement (Controlled Attenuation Parameter®) > 238 dB/m with an IQR < 30 dB/m. 6. Having an EHMG with some degree of fibrosis diagnosed by ET (Fibroscan®) > 5.2 kPa (the use of a Fibroscan® performed by usual clinical practice in the 3 months prior to the screening visit will be allowed). In patients in whom ET is not possible, have a FIB-4 >1.3. 7. Be able to understand and comply with the requirements and instructions of the protocol 8. Understand the long-term commitment to the study 9. Acceptance of your participation in the study by signing an informed consent
You likely can't join if
- 1. Having a chronic HBV infection (presence of HBsAg+) or HCV (detectable HCV viral load). The inclusion of patients with: • HCV treated and cured before 12/31/2019 whose liver stiffness measured by Fibroscan® was not greater than 9 kPa when they had active HCV infection. • HCV infection resolved spontaneously. 2. Having diabetes mellitus under treatment with SGLT2, GLP1 or plioglitazone for less than 6 months. 3. Have a history of alcohol abuse 4. Having a harmful consumption of alcohol, defined as >30 g of alcohol per day in men and more than >20 g of alcohol per day in women. 5. Having chronic decompensated liver disease, defined as any of the following: presence of encephalopathy, ascites, coagulopathy, esophageal or gastric varices, or persistent jaundice. 6. Any prior physical or mental condition (such as habitual drug use) that the investigator believes may interfere with the patient's ability to comply with the study protocol 7. Pregnant or lactating at the screening visit or at any time during the study or intent to become pregnant during the study period. 8. Previous history of rilpivirine use of any duration
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.